000919 金陵药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.3361.4251.1503.4103.556
总资产报酬率 ROA (%)0.8400.8910.6982.1162.342
投入资产回报率 ROIC (%)1.2491.3251.0853.2613.379

边际利润分析
销售毛利率 (%)22.37620.86118.45819.95619.773
营业利润率 (%)4.5592.1661.3094.6204.868
息税前利润/营业总收入 (%)4.2841.6620.5713.9374.064
净利润/营业总收入 (%)3.5331.6040.5474.0314.263

收益指标分析
经营活动净收益/利润总额(%)81.94758.365121.47368.22355.036
价值变动净收益/利润总额(%)4.79946.152134.99021.615-9.568
营业外收支净额/利润总额(%)-3.791-6.209-7.3820.538-1.755

偿债能力分析
流动比率 (X)3.8573.8913.5232.9823.043
速动比率 (X)3.6483.6523.2582.6952.753
资产负债率 (%)19.63519.72320.37019.67120.186
带息债务/全部投入资本 (%)4.6735.4315.5591.9763.146
股东权益/带息债务 (%)2,008.4741,714.6861,671.2154,859.0283,026.289
股东权益/负债合计 (%)320.080318.871305.665299.352326.399
利息保障倍数 (X)-39.434-4.405-0.881-5.558-5.643

营运能力分析
应收账款周转天数 (天)45.35547.68645.43436.89839.493
存货周转天数 (天)31.86535.90737.84238.11841.661